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Over the past decade, there has been awave
of high-quality evidence supporting omis-
sion of radiation therapy (RT) for early-
stage breast cancer.1-3 The arguments have
centered around the absence of a survival
benefit with RT over best medical ther-
apy, which has made the argument for
omitting RT persuasive, particularly for
elderly patients whose expected lifespan
does not typically justify the long-term
benefits of RT over the shorter-term
risks.1-3 The most prominent recent tri-
als have been the Cancer and Leukemia
Group B (CALGB) 9343 trial (studying
women age $70 years with estrogen
receptor–positive [ER1], clinical stage I
breast cancer), the Postoperative Radio-
therapy inMinimumRisk Elderly (PRIME)
II trial (studying women age $ 65 years
with ER1 tumors # 3 cm), and the Aus-
trian Breast and Colorectal Cancer Study
Group (ABCSG) Study 8A (women with
tumors , 3 cm, ER or progesterone re-
ceptor positive, and negative lymph nodes
were studied).1-3
These trials have built upon the foun-
dation of older trials such as the National
SurgicalAdjuvantBreast andBowelProject
B-21 trial4 (studying women with ER1
tumors# 1 cm regardless of age) and Fyles
et al.5 (studying woman age $ 50 with
ER1 tumors up to 4 cm), which were
among the first to assess the necessity for
RT in early-stage breast cancer for ap-
propriately selected patients.
An unexplored aspect of these recent
seminal trials is their applicability to
patients regardless of race or ethnic-
ity, particularly regarding nonwhite pa-
tient representation commensurate with
their demographic distribution in the
United States and the United Kingdom,
respectively1-3,6,7 (Table 1). Although the
typical socioeconomic profile of a patient
likely to receive RT favors white patients,
this should not result in the obfuscation of
nonwhite patients from consideration
when interpreting the relevance of these
trials to these populations. Although ge-
netic differences in tumor behavior by race
have been documented, often manifesting
as more aggressive tumor biology in un-
derrepresented minorities, data demon-
strating racial differences in outcomes
despite similar access to optimal care are
largely lacking.8-11
PRIME II and ABCSG 8A originated in
the United Kingdom and Austria, respec-
tively, where there are no federal mandates
requiring representative portions of mi-
norities to be included in high-quality
clinical trials; in fact, neither study even
reported the racial and ethnic demographics
of their combined 2,195 patients.2,3 The
same excuse cannot be made for studies
originating in the United States (such as
CALGB9343),where theNational Institutes
of Health (NIH) Revitalization Act of 1993
has required that members of minority
populations be adequately represented in
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clinical research.1,12 The failure of US trials to approximate
this standard has sadly not changed since the 20th century;
the proportion of underrepresented minority patients in
phase III cancer treatment and prevention clinical trials has
actually decreased from 1990 to 2010.12,13 Specifically, the
proportion of black patients in phase III cancer treatment and
prevention trials decreased from 10.5% (1990 to 2000) to 6.2%
(2000 to 2010), compared with their actual representation in
the US population of 11.7% in 1990 and 12.6% in 2010.6,13
Unfortunately, clinical trials with even larger numbers of
accrued patients often do not report patient racial and ethnic
demographics, such as the ongoing Trial Assigning In-
dividualized Options for Treatment (TAILORx) trial, which
contains more than 10,200 participants and has been touted as
the largest adjuvant breast cancer treatment trial ever con-
ducted.14 It would be wise for the NIH to revisit andmodify its
original mandate to optimally address this issue.
The fact that trials such as CALGB 9343, ABCSG 8A, and
PRIMEIIhavebeenwidelyacceptedasapplicable toallpatients
regardlessof the racial andethnicdistributions in theirmakeup
is a testament to how ineffective the NIHmandate has been in
adequately representing people of color (Table 1), who remain
markedly underrepresented in high-quality trials.13-15 The
direct advertisement of the CALGB results by organizations
such as the SusanG. Komen Foundationwithout comment on
this issue of representation is an example (Fig 1). Theremay be
some mitigating factors for early-stage breast cancer (ie, the
potential for racial differences in screening behaviors to result
in fewer early breast cancers diagnosed in nonwhite patients
$ 70 years compared with older white patients); however, the
overall inattentiveness of these trials to nonwhite patients
remains disturbing, even if some of this inattentiveness could
theoretically be attributable to the reticence of nonwhite
patients risking subjection to malicious, unethical clinical
studies in the vein of the Tuskegee Syphilis Study, which
concluded (only because of whistleblower activity) less than
25 years before CALGB 9343 enrollment began.
The reality of this observation can become a double-edged
sword: For nonwhite patients, particularly underrepresented
minorities meeting criteria for RT omission, can we legiti-
mately base a decision not to treat them on results of these
studies? Do we use this information to justify potentially
overtreating minority patients? Or do we continue with
business as usual, pretending that these studies adequately
reflect and represent these patient populations, even though
they clearly do not? There is no clear right answer, but it is
apparent from the sworn oath we took when we became
physicians that the wrong approach is to counsel nonwhite
patients without addressing this issue, thereby impairing their
ability to make the most informed medical decision possible.
Additional clinical work is needed to validate the results of
these studies when applied to real-world populations, which
Table 1. Recent Studies Providing Level 1 Evidence Supporting Omission of Radiation Therapy for Early-Stage
Breast Cancer and Their Representation (Percentage) by Race and Ethnicity ComparedWith theUS population as Defined by
the 2010 US Census and the UK Population as Defined by the 2011 UK Census
Race/Ethnicity US Census (2010)6 CALGB 9343 A (2013)1 UK Census (2011)7 PRIME II (2015)2 ABCSG 8A (2007)3
White 72.4 90.3 87.1 NR NR
Black 12.6 7.1 3.0 NR NR
Hispanic* 16.3 2.0 NR NR NR
Asian 4.8 0.3 6.9 NR NR
American Indian 0.9 , 0.4 (NR) NR NR NR
Total population, no. 308,745,538 636 63,182,178 1,326 869
Nation of origin US US UK UK Austria
Cancer type All Breast All Breast Breast
Median follow-up — 12.6 years — 5 years 53.8 months
NOTE. Data given as % unless otherwise indicated.
Abbreviations:—, not applicable; NR, not reported; UK, United Kingdom.
*Stratified in the US Census by ethnicity, which depicts Hispanic versus non-Hispanic people.
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consist of dramatically more nonwhite patients than in any of
these three randomized trials. Only then will the medical
community be able to apply actual evidence to the current
assumption that the level 1 evidentiary support ofRTomission
provided by CALGB 9343, ABCSG 8A, and PRIME II is ap-
plicable to nonwhite patients. Furthermore, a reversal of the
disturbing decade-long trend of disproportionate scarcity of
funding for RT trials compared with other oncological clinical
trials would greatly aid in improving the applicability of these
trials to nonwhite patients.16 Powering of future trials for
subset analyses from the onset would increase accrual of
nonwhite patients and establish the applicability of these trials
to underrepresented minorities, who may have different tu-
mor biology from white patients. Such powering would also
highlight the dearth of representation of minorities, as it
would undoubtedly cause delays in trial onset unless trial
Fig 1. Direct advertisement of CALGB 9343 study results shortly after publication on the Susan G. Komen Foundation website.
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investigators redoubled their efforts to actively recruit mi-
nority patients into their studies. Linking the dearth of
minority participation in clinical trials to the professional
and financial reputation associated with timely physician
completion of trials may provide an incentive to address this
problem, which, to our knowledge, has been previously
unexplored. The relative failure of programs such as the
minority-based centers of the National Cancer Institute
Community Oncology Research Program to improve the
dearth of minority-patient representation in clinical trials
indicates the complexity of this problem, which requires
multifarious and innovative solutions. Given the present
dearth of minorities in clinical trials, a potential solution
could involve increased use of registry data, claims data, and
aggregators of electronic medical record data. Although
these sets have significant limitations (ie, the lack of reliable
recurrence data in the National Cancer Database and SEER),
their superior inclusion of minorities may help fill the
representation gap until clinical trials have progressed to the
point where minorities are adequately represented.
In our view, the optimal philosophy of a physician facing
these situations will mirror the immortal words of an in-
fluential human rights activist: “I’m for truth, no matter who
tells it. I’m for justice, no matter who it is for or against. I’m a
human being, first and foremost, and as such I’m for whoever
and whatever benefits humanity as a whole.”17
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